Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas
Recruiting · NCT06914674 · Interventional (participants receive a specific treatment) · Lead sponsor: Fudan University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Tamoxifen for Solid Pseudopapillary Tumor of the Pancreas
Who can take part
Age range
14 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age 14-80 years.
- Histologically confirmed advanced SPTP with ER/PR+.
- Advanced disease:
- Unresectable primary tumor or distant metastasis (liver, lung, peritoneum, etc.).
- Recurrent or refractory after prior surgery/systemic therapy.
- ≥1 measurable lesion.
- ECOG performance status 0-2.
- Life expectancy ≥1 month.
- Able to comply with study visits and oral medication.
Exclusion criteria
- Non-SPTP pathology.
- Active gastrointestinal inflammation/infection (e.g., pancreatitis).
- Pregnancy/lactation.
- Severe organ dysfunction (renal, cardiac, hepatic, or pulmonary).
- Uncontrolled comorbidities (e.g., CNS disorders, unstable angina).
- Conditions compromising patient safety or data integrity.
Where it is running
1 location listed.
- Shanghai Cancer Center - Shanghai, China